Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)
Abstract Introduction Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized. Methods A retrospec...